爱斯坦-巴尔病毒脑炎作为状态的原因 - - 一个罕见的遭遇
Ayisha Farooq Khan1, Tooba Arshad1, Faryal Abdy1
1Section of Neurology, Department of Medicine, Aga Khan University, National Stadium Road, Karachi, Pakistan.
Archives of Iranian medicine
|February 26, 2025
概括
爱斯坦-巴尔病毒 (EBV) 脑炎很少会导致状态,长时间的发作状态. 这一案例凸显了在神经病例中考虑EBV的必要性,即使没有免疫缺陷.
科学领域:
- 神经学 神经学
- 传染性疾病 传染性疾病
- 病毒学 病毒学
背景情况:
- 爱斯坦-巴尔病毒 (EBV) 与传染性单核病和罕见的神经问题有关.
- EBV脑炎并不常见,而状态作为一种表现是非常罕见的,全球报告不到十个.
研究的目的:
- 在18岁的女性中报告一种罕见的EBV脑炎病例,呈现为状态.
- 要强调在 status epilepticus 中考虑EBV脑炎的重要性,无论免疫状况如何.
主要方法:
- 一个18岁的女性患有发烧和发作,进展到 status epilepticus 的病例报告.
- 脑脊液 (CSF) 分析显示淋巴细胞占主导地位.
- 大脑成像 (MRI/CT) 显示双边对称的超强度在尾状和状.
- 对EBV (IgG和IgM) 的血清检测证实了阳性.
主要成果:
- 患者出现了发烧,,以及随后的状态.
- 脑液分析显示了淋巴细胞多细胞化.
- 脑部成像显示,在基底质中,有着特征性的双边对称性损伤.
- 阳性EBV血清学支持EBV脑炎的诊断.
结论:
- 在对 status epilepticus 的差异诊断中,即使在免疫能力强的个体中,也应该考虑EBV脑炎.
- 通过CSF分析和血清学等适当的调查及时诊断至关重要.
- 用抗病毒药物 (如甘西克洛维尔) 和抗药的早期治疗可以导致患者的改善.
相关概念视频
Seizures: Classification
297
Epilepsy is primarily characterized by unpredictable seizures, either provoked by an identifiable factor, such as injury or illness, or unprovoked, occurring spontaneously without apparent cause.
Seizures are typically classified into two main categories: focal and generalized seizures.
Focal Seizures
Focal seizures originate from specific regions of the brain. These seizures are further sub-classified into two types:
Seizures are typically classified into two main categories: focal and generalized seizures.
Focal Seizures
Focal seizures originate from specific regions of the brain. These seizures are further sub-classified into two types:
297
Arteries of the Lower Limbs
176
Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
176
Electroconvulsive Therapy
22
Electroconvulsive therapy (ECT), or shock therapy, remains a critical biomedical intervention for severe, treatment-resistant depression. While its origins can be traced back to Hippocrates' observations that malaria-induced convulsions alleviated mental illness, modern ECT has evolved significantly from its earlier, more primitive applications. First introduced in 1938 by Ugo Cerletti and his colleagues, ECT involves inducing controlled seizures using electrical currents. In its early...
22
Antiepileptic Drugs: GABAergic Pathway Potentiators
307
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
307
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
209
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
209


